Nidek claims Canadian patent victory sets US precedent
This article was originally published in Clinica
Executive Summary
Nidek claims that the decision announced last week to uphold an earlier patent lawsuit in Canada in its favour against Visx opens the way to victory in similar litigation in the US. For its part, Visx dismisses the decision as a "non-event for both parties", and accuses the Japanese company of making "misleading and inaccurate" comments in its press release.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.